MetaCap

Compugen Ltd. (CGEN)

NASDAQ: CGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.84-0.04 (-2.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CGEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$174.29M
52-week range
1.43 – 3.24
Day range
1.81 – 1.88
Volume / Avg
188.25K / 223.56K
Beta
—

52-week range

$1.43$3.24

CGEN stock today

Shares of Compugen (CGEN) finished lower on Nov 20 at $1.84, a drop of 2.13% or $0.04 per share, versus the S&P 500's 3.70% decline. Shares are 43.2% below their 52-week high of $3.24, set on Apr 24, 2026 and 28.7% above the 52-week low of $1.43, in the middle of the past year's range. CGEN is up 20.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.3%.

Compugen trades at 4.7x its trailing twelve-month earnings per share of $0.39.

Summary generated from market data by MetaCap's automated system. Methodology

About Compugen

Company profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Eran Ophir Ph.D.
Headquarters
Holon
Employees
75
IPO year
2000
Website
cgen.com

Financial highlights

Full financials

In fiscal 2025, Compugen generated $72.8 million in revenue, up 161.1% from fiscal 2024. Net income was $35.3 million, for a net margin of 48.6% versus a median of -449.3% in the prior 5 years. Gross margin was 87.3% (up from 71.5%) and operating margin 43.1%.

Compugen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$72.76M$27.86M$33.46M$7.50M$6.00M
Growth+161.14%-16.72%+346.12%+25.00%+200.00%
Net income$35.34M$-14.23M$-18.75M$-33.69M$-34.20M
EPS (diluted)$0.38$-0.16$-0.21$-0.39$-0.41

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$4.80+160.87%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.07 vs $-0.08
Surprise
+12.50%

CGEN news

All CGEN news

Compugen peers

Health Care sector
CGEN peer companies
CompanyPrice% ChgMarket capCompare
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs CGEN
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs CGEN
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs CGEN
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs CGEN
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs CGEN
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs CGEN
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs CGEN
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs CGEN

Indexes, lists and sector

Compugen stock FAQ

What is Compugen's stock price today?

CGEN last traded at $1.84 as of Nov 20, 4:00 PM EST, down 2.13% on the day. Prices are delayed at least 15 minutes.

What is CGEN's P/E ratio?

CGEN trades at a trailing P/E ratio of 4.72.

Who is Compugen's CEO?

Dr. Eran Ophir Ph.D. is the chief executive officer of Compugen Ltd., which has about 75 employees.

What is the CGEN 52-week high?

The 52-week high for CGEN is $3.24 and the 52-week low is $1.43. The stock is currently 43.2% below its high.

Compare CGEN